Videos

The postdoctoral researcher at Laboratory for Translational Cancer Immunology, Ludwig-Maximilians-Universität München, discussed further research his group is conducting with cell therapy.

The Medical Director of Pediatric Hematology/Oncology at Sarah Cannon Research Institute discussed his experience with and reaction to the approval of Casgevy.

The chief hematology/oncology fellow at University of Chicago discussed real-world experience data and new analyses of patients with B-cell acute lymphoblastic leukemia treated with brexu-cel.

The clinical associate professor at Stanford Medicine discussed new research on patients who have received HCT or gene therapy for SCD.

The internal medicine resident physician at University of Kansas Medical Center discussed research conducted into gender authorship rates of 13 pivotal trials published between 2017 and 2022.

The cofounder, executive vice president, and chief medical officer, CLL Society, discussed updates in CLL research in the field in general and presented at the ASH 2023 meeting.

The chief of hematology at Children’s Hospital of Philadelphia discussed dual approval of the 2 gene therapies that coincided with ASH’s 2023 conference.

The associate professor at Peter MacCallum Cancer Centre discussed further research and questions that need to be investigated with the cell therapy.

The associate professor at Fred Hutch Cancer Center discussed new data on the CD20-targeting CAR he presented at ASH 2023.

The chief of hematology at Children’s Hospital of Philadelphia discussed the updated results she presented at ASH’s 2023 conference.

The medical Director and interim co-Chief Medical Officer at Seattle Children's Therapeutics discussed possible research to move forward with CD19 T-APCs for patients with B-ALL.

The professor of hematology at University of Lille and chair of LYSA also discussed what the group will be focusing on in 2024.

The postdoctoral researcher at Laboratory for Translational Cancer Immunology, Ludwig-Maximilians-Universität München, discussed the need for research into how CAR T-cells act differently between sexes.

The Medical Director of Pediatric Hematology/Oncology at Sarah Cannon Research Institute discussed new data from CLIMB-121 presented at ASH 2023 supporting Casgevy's approval.

The hematologist at the University of Navarra discussed updated data from the phase KarMMa-3 trial.

The chief medical officer of Orca Bio discussed some trends he was excited about at ASH’s 2023 conference.

The chief hematology/oncology fellow at University of Chicago discussed new data from the ROCCA collaborative study presented at ASH 2023.

The hematologist and cell therapist from the University of Miami Sylvester Comprehensive Cancer Center spoke about long-term outcome data he presented at ASH’s 2023 conference.

The professor of pediatric hematology/oncology at CS Mott Children’s Hospital discussed 3-year follow-up data from the HOPE B trial of the approved gene therapy, branded as Hemgenix.

The chief medical officer of Orca Bio discussed data the company presented on its Orca-T and Orca-Q programs at ASH 2023.

The associate professor at Peter MacCallum Cancer Centre discussed case study research from the center and possible contributions to the case.

The professor of hematology at University of Lille and chair of LYSA shared updated data from the TRANSCEND-FL trial.

The bone marrow transplant physician at St. Jude Children’s Research Hospital also discussed the recent approval of exa-cel.

The medical Director and interim co-Chief Medical Officer at Seattle Children's Therapeutics discussed complete data from the PLAT-03 feasibility trial assessing SCRI-CAR19 and CD19t T-APCs in B-ALL.

The postdoctoral researcher at Laboratory for Translational Cancer Immunology, Ludwig-Maximilians-Universität München, discussed an analysis of female and male patient outcomes after axi-cel therapy.

The bone marrow transplant physician at St. Jude Children’s Research Hospital discussed an analysis of the sickle cell disease gene therapy he’s presenting on at ASH’s 2023 meeting.

The president and head of R&D at Taysha Gene Therapies discussed the early clinical evaluation of TSHA-102.

The associate professor of dermatology at Stanford University discussed his experiences investigating and helping to develop Vyjuvek, approved for treating DEB.